{"id":62113,"date":"2019-09-17T11:05:10","date_gmt":"2019-09-17T15:05:10","guid":{"rendered":"http:\/\/www.bu.edu\/law\/?p=62113"},"modified":"2019-09-17T11:05:10","modified_gmt":"2019-09-17T15:05:10","slug":"procarta-receives-carb-x-award-of-up-to-9-2-million","status":"publish","type":"post","link":"https:\/\/www.bu.edu\/law\/2019\/09\/17\/procarta-receives-carb-x-award-of-up-to-9-2-million\/","title":{"rendered":"Procarta Receives CARB-X Award of up to $9.2 Million"},"content":{"rendered":"<p><strong>Stevenage, UK, 17th September 2019 \/ Sciad Newswire \/ Procarta Biosystems<\/strong>, a privately held UK-based biotech company, today announced a CARB-X award of up to $9.2 million to progress its pipeline of antibiotic precision medicines. The award includes initial non-dilutive funding up to $2.2 million with a further $7.0 million available if certain project milestones are met. The new antibiotics are based on Procarta&#8217;s proprietary oligonucleotide-based antimicrobial platform and will target potentially life-threatening infections caused by Gram-negative ESKAPE pathogens.<\/p>\n<p>&#8220;This new award from CARB-X recognises the value of the novel modalities in our pipeline and their potential to precipitate a paradigm shift in antimicrobial treatments&#8221;, said Dr Andrew Lightfoot, PhD, MBA, Chief Executive Officer of Procarta. &#8220;We are delighted to have support from CARB-X recognising the importance of developing new antibiotics to combat antimicrobial resistance.&#8221;<\/p>\n<p><a href=\"https:\/\/www.firstwordpharma.com\/node\/1666800?tsid=28&amp;region_id=3\" target=\"_blank\" rel=\"noopener\">Read more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Stevenage, UK, 17th September 2019 \/ Sciad Newswire \/ Procarta Biosystems, a privately held UK-based biotech company, today announced a CARB-X award of up to $9.2 million to progress its pipeline of antibiotic precision medicines. The award includes initial non-dilutive funding up to $2.2 million with a further $7.0 million available if certain project milestones [&hellip;]<\/p>\n","protected":false},"author":11260,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2367],"tags":[1771],"_links":{"self":[{"href":"https:\/\/www.bu.edu\/law\/wp-json\/wp\/v2\/posts\/62113"}],"collection":[{"href":"https:\/\/www.bu.edu\/law\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bu.edu\/law\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/law\/wp-json\/wp\/v2\/users\/11260"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/law\/wp-json\/wp\/v2\/comments?post=62113"}],"version-history":[{"count":1,"href":"https:\/\/www.bu.edu\/law\/wp-json\/wp\/v2\/posts\/62113\/revisions"}],"predecessor-version":[{"id":62114,"href":"https:\/\/www.bu.edu\/law\/wp-json\/wp\/v2\/posts\/62113\/revisions\/62114"}],"wp:attachment":[{"href":"https:\/\/www.bu.edu\/law\/wp-json\/wp\/v2\/media?parent=62113"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bu.edu\/law\/wp-json\/wp\/v2\/categories?post=62113"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bu.edu\/law\/wp-json\/wp\/v2\/tags?post=62113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}